Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

被引：0
|
作者：
Liu, Wei [1 ]
Wang, Yi [1 ]
Xu, Yan [1 ]
Du, Chenxing [1 ]
Wang, Qi [1 ]
Wang, Tingyu [1 ]
Huang, Wenyang [1 ]
Zhang, Shuaishuai [1 ]
Yi, Shuhua [1 ]
Yan, Yuting [1 ]
Yu, Tengteng [1 ]
Sui, Weiwei [1 ]
An, Gang [1 ]
Lyu, Rui [1 ]
Liu, Huimin [1 ]
Xiong, Wenjie [1 ]
Fu, Mingwei [1 ]
Zou, Dehui [1 ]
Qiu, Lugui [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185669
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy and Safety of Clofarabine in Relapsed and/or Refractory Non-Hodgkin Lymphoma, Including Rituximab-Refractory Patients
    Nabhan, Chadi
    Davis, Nancy
    Bitran, Jacob D.
    Galvez, Angel
    Fried, Walter
    Tolzien, Kathy
    Foss, Susan
    Dewey, Wendy M.
    Venugopal, Parameswaran
    CANCER, 2011, 117 (07) : 1490 - 1497
  • [42] COMPLETE RESPONSE TO IGEV (IFOSFAMIDE, GEMCITABINE AND VINORELBINE) AND OUTCOME IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Anastasia, A.
    Mazza, R.
    Giordano, L.
    Balzarotti, M.
    Magagnoli, M.
    Castagna, L.
    Spina, M.
    Tirelli, U.
    Santoro, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 37 - 37
  • [43] Results of GROC-rev salvage regimen: Gemcitabine, rituximab, and oxaliplatin chemotherapy with revlimid for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).
    Cabanillas, Fernando
    Liboy, Idalia
    Cruz, Alexis
    Solivan, Pedro Gil
    Rivera, Noridza
    Pardo, Wandaly Ibis
    Acosta, Mirelis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Bortezomib and rituximab (R-velcade) in relapsed and refractory non Hodgkin's lymphoma
    Merla, E.
    La Sala, A.
    Dell'Olio, M.
    Bodenizza, A.
    Carella, A. M.
    Falcone, A.
    Greco, M. M.
    Mantuano, S.
    Melillo, L.
    Nobile, M.
    Sanpaolo, G.
    Scalzulli, P. R.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 213 - 213
  • [45] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study
    Corazzelli, G.
    Russo, F.
    Capobianco, G.
    Marcacci, G.
    Della Cioppa, P.
    Pinto, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 18 - 24
  • [46] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective salvage regimen for relapsed and refractory Hodgkin and non-Hodgkin's lymphoma: Results of a pilot study
    Corazzelli, G.
    Capobianco, G.
    Marcacci, G.
    Frigeri, F.
    Arcamone, M.
    Becchimanzi, C.
    Pinto, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 235 - 235
  • [47] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study
    Corazzelli, G
    Russo, F
    Capobianco, G
    Marcacci, G
    Della Cioppa, P
    Pinto, A
    BLOOD, 2005, 106 (11) : 276A - 277A
  • [48] Efficacy and safety of gemcitabine containing regimen for refractory and relapsed non-Hodgkin lymphoma
    Mizutani, Chisato
    Nishi, Katsuyuki
    Takahashi, Satoshi
    Mitani, Sachiko
    Tada, Kohei
    Kaneko, Hitomi
    Hatanaka, Kazuo
    Ukyo, Naoya
    Hirata, Hirokazu
    Tsudo, Mituru
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [49] Lenalidomide response in relapsed/refractory aggressive non-Hodgkin's lymphoma is related to tumor burden and time from rituximab treatment
    Wiernik, Peter H.
    Lossos, Izidore S.
    Tuscano, Joseph M.
    Justice, Glen
    Vose, Julie M.
    Cole, Craig E.
    McBride, Kyle
    Wride, Kenton
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Habermann, Thomas M.
    BLOOD, 2007, 110 (11) : 756A - 756A
  • [50] An update on gemcitabine, rituximab, and oxaliplatin in combination for relapsed/refractory non-Hodgkin lymphomas.
    Crescentini, Robert M.
    Sweet, Kendra Lynn
    Liu, Jijun
    Liboy, Idalia
    Dalia, Samir
    Chavez, Julio C.
    Bello, Celeste M.
    Sokol, Lubomir
    Sotomayor, Eduardo M.
    Cabanillas, Fernando
    Cultrera, Jennifer L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345